A Study of GV20-0251 in Patients With Solid Tumor Malignancies

Inclusion Criteria:

1. >= 18 years of age
2. previously treated, histologically-confirmed advanced solid malignancy with progressive disease requiring therapy
3. refractory or intolerant to standard therapy(ies)
4. one or more metastatic solid tumors that are evaluable or measurable per RECIST v1.1
5. ECOG performance status of 0 or 1
6. Life expectancy of >=12 weeks
7. Disease-free of active second/secondary or prior malignancies for ≥ 2 years
8. laboratory test results within the required parameters
9. Women of child bearing potential (WOCBP) and men must agree to use adequate contraception

Exclusion Criteria:

1. Participant with acute luekemia or CLL
2. Participant with heart disease or unstable arrhythmia
3. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic therapy
4. Participant has active autoimmune disease or other medical conditions requiring chronic systemic steroid or immunosuppressive therapy
5. Known human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection
6. History of major organ transplant
7. History of a bone marrow transplant
8. Symptomatic central nervous system (CNS) malignancy or metastasis
9. Serious nonmalignant disease
10. Pregnant or nursing women
11. Treatment with PD-1 and equivalent immune modulators or major surgery prior to the first dose of study medication
12. Participants who are currently receiving any other investigational agent or have received an investigational agent within 4 weeks prior to the first dose of study medication
13. Treatment with any anticancer treatments with 2-weeks prior to the first dose of study medication
14. Radiation for symptomatic lesions must have been completed prior to the first dose of study medication
15. Active substance abuse